Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation.

Article Details

Citation
Copy to clipboard

Webster LR

Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation.

Expert Opin Investig Drugs. 2007 Aug;16(8):1277-83.

PubMed ID
17685875 [ View in PubMed
]
Abstract

Oxytrex (Pain Therapeutics, Inc.) is an oral opioid that combines a therapeutic amount of oxycodone with an ultra-low dose of the antagonist naltrexone. Animal data indicate that this combination minimizes the development of physical dependence and analgesic tolerance while prolonging analgesia. Oxytrex is in late-stage clinical development by Pain Therapeutics for the treatment of moderate-to-severe chronic pain. To evaluate the safety and efficacy of the oxycodone/naltrexone combination, three clinical studies have been conducted, one in healthy volunteers and the other two in patients with chronic pain. The putative mechanism of ultra-low-dose naltrexone is to prevent an alteration in G-protein coupling by opioid receptors that is associated with opioid tolerance and dependence. Opioid agonists are initially inhibitory but become excitatory through constant opioid receptor activity. The agonist/antagonist combination of Oxytrex may reduce the conversion from an inhibitory to an excitatory receptor, thereby decreasing the development of tolerance and physical dependence.

DrugBank Data that Cites this Article

Drugs